Inovio Pharmaceuticals Inc
INO
Get informed when a big investor buys or sells
+ FollowMarket Cap$36.28M
Close$
$0.74
6.1% upside
Current Fair Value
6.1% upsideUndervalued by 6.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $36.28 Million |
|---|---|
| Enterprise Value | $-17,534,528,662.00 |
| Dividend Yield | $0.28 (-) |
| Earnings per Share | $-1.81 |
| Beta | 1.49 |
| Outstanding Shares | 69,101,910 |
Return
| Return on Equity | -1399.93% |
|---|---|
| Return on Assets | -170.65% |
| Return on Invested Capital | -732.44% |
Valuation & Multiples
| P/E Ratio | -0.4 |
|---|---|
| PEG | 0.4 |
| Price to Sales | -0.7 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 268345.94 |
| Enterprise Value to EBIT | 0.2 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.5 |
| Debt to Equity | 1.43 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 18, 2026
EPS Estimate
$-0.37
Average shareholder expectationRevenue Estimate
$333,333
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.25
Average shareholder expectationRevenue Estimate
$533,333
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 55.42% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 4.53% |
|---|---|
| Total Invested | $56,655▼ 99.90% |
| Investors Holding | 24▼ 83.00% |
ESG Score
No data
About Inovio Pharmaceuticals Inc
CEO: Jong Kim